Prostate Cancer

Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease (CRPC). Docetaxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies.
Read Article

Prostate cancer is the third most common type of cancer in the United States, after breast cancer and lung cancer. In 2018 alone, 164,690 individuals were diagnosed with prostate cancer, accounting for nearly 10% of all new cancer cases, and 29,430 deaths were attributed to the disease. Prostate cancer is most frequently diagnosed in men aged 65 to 74 years (median age, 66 years). More than 98% of patients with prostate cancer survive ≥5 years; however, the 5-year survival rate drops to 30% for patients with metastatic disease.
Read Article

San Francisco, CA—Darolutamide, an investigational androgen receptor inhibitor, significantly improved metastasis-free survival in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC) compared with placebo in a large phase 3 clinical trial.
Read Article

Nearly 12% of American men will be diagnosed with prostate cancer at some point during their lives. Prostate cancer may remain indolent, but it often requires treatment, as evidenced by the more than 26,000 deaths attributable to this disease annually. Although the 5-year survival is high for men with localized prostate cancer, this drops to 29% in men with metastatic prostate cancer. Even with treatment, prostate cancer progresses in more than 33% of men. The median time to metastatic disease is approximately 8 to 10 years after the detection of biochemical recurrence.
Read Article

Chicago, IL—The results from 2 studies should advance the use of abiraterone acetate (Zytiga) to the frontline treatment of patients with hormone-sensitive advanced prostate cancer, effectively replacing chemotherapy, said several experts at the 2017 ASCO annual meeting.
Read Article



Patient-reported outcomes had significant associations with survival in metastatic castration-resistant prostate cancer (mCRPC), suggesting potential implications for clinical management, reported Tomasz M. Beer, MD, Oregon Health & Science University, Knight Cancer Institute, Portland, and colleagues, at the 2016 International Society for Pharmacoeconomics and Outcomes Research annual meeting.
Read Article

The incidence of metastatic prostate cancer increased by >70% from 2004 to 2013, including >90% in the age-group most likely to benefit from definitive treatment, according to a new analysis of a national database (Weiner AB, et al. Prostate Cancer Prostatic Dis. 2016 Jul 19. Epub ahead of print).
Read Article

Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.
Read Article

Page 3 of 8